Immuneering (IMRX) Competitors $2.04 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IMRX vs. RPID, QNCX, GBIO, ADAG, IPHA, FATE, BNTC, PYXS, ACB, and TRVIShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Rapid Micro Biosystems (RPID), Quince Therapeutics (QNCX), Generation Bio (GBIO), Adagene (ADAG), Innate Pharma (IPHA), Fate Therapeutics (FATE), Benitec Biopharma (BNTC), Pyxis Oncology (PYXS), Aurora Cannabis (ACB), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector. Immuneering vs. Rapid Micro Biosystems Quince Therapeutics Generation Bio Adagene Innate Pharma Fate Therapeutics Benitec Biopharma Pyxis Oncology Aurora Cannabis Trevi Therapeutics Rapid Micro Biosystems (NASDAQ:RPID) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking. Do institutionals and insiders believe in RPID or IMRX? 52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 30.4% of Rapid Micro Biosystems shares are held by company insiders. Comparatively, 25.0% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor RPID or IMRX? In the previous week, Immuneering had 8 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 8 mentions for Immuneering and 0 mentions for Rapid Micro Biosystems. Immuneering's average media sentiment score of 0.75 beat Rapid Micro Biosystems' score of 0.00 indicating that Immuneering is being referred to more favorably in the news media. Company Overall Sentiment Rapid Micro Biosystems Neutral Immuneering Positive Which has more volatility & risk, RPID or IMRX? Rapid Micro Biosystems has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Does the MarketBeat Community prefer RPID or IMRX? Immuneering received 25 more outperform votes than Rapid Micro Biosystems when rated by MarketBeat users. Likewise, 65.91% of users gave Immuneering an outperform vote while only 26.67% of users gave Rapid Micro Biosystems an outperform vote. CompanyUnderperformOutperformRapid Micro BiosystemsOutperform Votes426.67% Underperform Votes1173.33% ImmuneeringOutperform Votes2965.91% Underperform Votes1534.09% Which has higher earnings and valuation, RPID or IMRX? Rapid Micro Biosystems has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapid Micro Biosystems$26.17M1.78-$52.47M-$1.12-0.96Immuneering$320K197.94-$53.47M-$1.97-1.04 Do analysts recommend RPID or IMRX? Immuneering has a consensus target price of $12.80, suggesting a potential upside of 527.45%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Rapid Micro Biosystems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapid Micro Biosystems 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immuneering 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Is RPID or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Rapid Micro Biosystems' net margin of -184.93%. Rapid Micro Biosystems' return on equity of -48.05% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Rapid Micro Biosystems-184.93% -48.05% -39.18% Immuneering N/A -79.19%-69.08% SummaryImmuneering beats Rapid Micro Biosystems on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.34M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-1.0410.69125.6917.78Price / Sales197.94243.731,179.7874.25Price / CashN/A22.1633.7732.53Price / Book0.665.474.684.68Net Income-$53.47M$153.61M$119.54M$226.08M7 Day Performance19.30%-4.32%-2.46%-2.04%1 Month Performance-8.93%-8.61%-4.08%0.06%1 Year Performance-63.44%28.79%29.82%24.60% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.1656 of 5 stars$2.04flat$12.80+527.5%-63.4%$63.34M$320,000.00-1.0460Analyst ForecastRPIDRapid Micro Biosystems0.9505 of 5 stars$1.08-1.8%N/A+5.9%$47.34M$22.52M0.00193QNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$80.96MN/A-1.4860GBIOGeneration Bio3.359 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$90.17M$18.58M-0.62150ADAGAdagene2.974 of 5 stars$2.09-5.9%$5.00+139.2%+52.6%$92.53M$815,746.000.00260News CoveragePositive NewsGap UpIPHAInnate Pharma2.2362 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$120.64M$66.71M0.00220News CoverageGap UpFATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$252.84M$63.53M-1.35550Analyst UpgradeBNTCBenitec Biopharma2.2948 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$247.53M$80,000.000.0020Positive NewsPYXSPyxis Oncology1.0428 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A0.0060News CoverageGap UpHigh Trading VolumeACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073TRVITrevi Therapeutics3.4144 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A0.0020 Related Companies and Tools Related Companies RPID Alternatives QNCX Alternatives GBIO Alternatives ADAG Alternatives IPHA Alternatives FATE Alternatives BNTC Alternatives PYXS Alternatives ACB Alternatives TRVI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts